首页 > 最新文献

Journal of diabetes and clinical research最新文献

英文 中文
Ephrin B1 Regulates Inflammatory Pathways in Retinal Müller Cells. Ephrin B1 调节视网膜 Müller 细胞的炎症通路
Pub Date : 2024-01-01 DOI: 10.33696/diabetes.6.056
Li Liu, Youde Jiang, Mohamed Al-Shabrawey, Jena J Steinle

The role of inflammation has been accepted as a factor in the complications of diabetic retinopathy. Discovery of the upstream regulation of these inflammatory factors has remained a challenge. In this study, we explored the actions of ephrin B1 in retinal Müller cells and their actions on inflammatory proteins. We used diabetic human and mouse samples, as well as Müller cells in culture to measure ephrin B1 in Müller cells. We then generated Müller cell specific ephrin B1 knockout mice. We measure levels of key inflammatory proteins, including high mobility group box 1 (HMGB1) and NOD-like receptor protein 3 (NLRP3) pathway proteins in retinal lysates from the ephrin B1 floxed and ephrin B1 Müller cell specific knockout mice. Data show that ephrin B1 is significantly increased in the retina of diabetic humans and mice, as well as in Müller cells grown in high glucose. Elimination of ephrin B1 in mouse Müller cells led to a significant decline in all inflammatory proteins studied. In conclusion, a reduction in ephrin B1 in the diabetic retina may offer a new therapeutic modality for diabetic retinopathy.

炎症在糖尿病视网膜病变并发症中的作用已被公认。但发现这些炎症因子的上游调控机制仍是一项挑战。在这项研究中,我们探讨了 ephrin B1 在视网膜 Müller 细胞中的作用及其对炎症蛋白的作用。我们利用糖尿病人和小鼠样本以及培养中的Müller细胞来测量Müller细胞中的ephrin B1。然后,我们生成了 Müller 细胞特异性 ephrin B1 基因剔除小鼠。我们测量了ephrin B1基因缺失小鼠和ephrin B1 Müller细胞特异性基因敲除小鼠视网膜裂解液中关键炎症蛋白的水平,包括高迁移率组盒1(HMGB1)和NOD样受体蛋白3(NLRP3)通路蛋白。数据显示,ephrin B1 在糖尿病人和小鼠视网膜中以及在高糖生长的 Müller 细胞中明显增加。消除小鼠Müller细胞中的表皮生长因子B1会导致研究的所有炎症蛋白显著下降。总之,减少糖尿病视网膜中的表皮生长因子 B1 可为糖尿病视网膜病变提供一种新的治疗方法。
{"title":"Ephrin B1 Regulates Inflammatory Pathways in Retinal Müller Cells.","authors":"Li Liu, Youde Jiang, Mohamed Al-Shabrawey, Jena J Steinle","doi":"10.33696/diabetes.6.056","DOIUrl":"10.33696/diabetes.6.056","url":null,"abstract":"<p><p>The role of inflammation has been accepted as a factor in the complications of diabetic retinopathy. Discovery of the upstream regulation of these inflammatory factors has remained a challenge. In this study, we explored the actions of ephrin B1 in retinal Müller cells and their actions on inflammatory proteins. We used diabetic human and mouse samples, as well as Müller cells in culture to measure ephrin B1 in Müller cells. We then generated Müller cell specific ephrin B1 knockout mice. We measure levels of key inflammatory proteins, including high mobility group box 1 (HMGB1) and NOD-like receptor protein 3 (NLRP3) pathway proteins in retinal lysates from the ephrin B1 floxed and ephrin B1 Müller cell specific knockout mice. Data show that ephrin B1 is significantly increased in the retina of diabetic humans and mice, as well as in Müller cells grown in high glucose. Elimination of ephrin B1 in mouse Müller cells led to a significant decline in all inflammatory proteins studied. In conclusion, a reduction in ephrin B1 in the diabetic retina may offer a new therapeutic modality for diabetic retinopathy.</p>","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10947218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Commentary on “Better TIR, HbA1c, and Less Hypoglycemia in Closed-loop Insulin System in Patients with Type 1 Diabetes: A Meta-analysis” “1型糖尿病患者闭环胰岛素系统中TIR、HbA1c更好、低血糖更少:荟萃分析”综述
Pub Date : 2023-08-01 DOI: 10.33696/diabetes.4.055
Xiaojuan Jiao, Yunfeng Shen
Our team's previous meta-analysis aimed to evaluate the efficacy and safety of closed-loop insulin system (CLS) in non-pregnant individuals with type 1 diabetes mellitus (T1DM). In this study, we aim to discuss the broader application of CLS in a more diverse population and address the current challenges and future development directions. Through a comprehensive review of relevant literature, our findings indicate that CLS not only effectively lowers glucose levels in T1DM patients but also demonstrates greater effectiveness and safety when utilized in pregnant women with T1DM, patients with type 2 diabetes mellitus (T2DM), those undergoing hemodialysis, or individuals requiring surgery. Recent studies have also explored the impact of CLS therapy on quality of life, neurological function, and C-peptide levels. Nevertheless, despite these promising results, CLS still encounters challenges in clinical practice, such as technological maturity, cost-effectiveness, and personalized treatment approaches. Therefore, further research and development of CLS technology are imperative to facilitate its broader adoption among diverse populations and address the current obstacles to its implementation.
我们团队之前的荟萃分析旨在评估闭环胰岛素系统(CLS)在非妊娠1型糖尿病(T1DM)患者中的有效性和安全性。在本研究中,我们旨在探讨CLS在更多样化人群中的更广泛应用,并解决当前面临的挑战和未来的发展方向。通过对相关文献的全面回顾,我们的研究结果表明,CLS不仅能有效降低T1DM患者的血糖水平,而且在T1DM孕妇、2型糖尿病患者、血液透析患者或需要手术的患者中也显示出更大的有效性和安全性。最近的研究也探讨了CLS治疗对生活质量、神经功能和c肽水平的影响。然而,尽管取得了这些令人鼓舞的成果,CLS在临床实践中仍然面临着技术成熟度、成本效益和个性化治疗方法等方面的挑战。因此,进一步研究和开发CLS技术是必要的,以促进其在不同人群中更广泛的采用,并解决目前实施的障碍。
{"title":"A Commentary on “Better TIR, HbA1c, and Less Hypoglycemia in Closed-loop Insulin System in Patients with Type 1 Diabetes: A Meta-analysis”","authors":"Xiaojuan Jiao, Yunfeng Shen","doi":"10.33696/diabetes.4.055","DOIUrl":"https://doi.org/10.33696/diabetes.4.055","url":null,"abstract":"Our team's previous meta-analysis aimed to evaluate the efficacy and safety of closed-loop insulin system (CLS) in non-pregnant individuals with type 1 diabetes mellitus (T1DM). In this study, we aim to discuss the broader application of CLS in a more diverse population and address the current challenges and future development directions. Through a comprehensive review of relevant literature, our findings indicate that CLS not only effectively lowers glucose levels in T1DM patients but also demonstrates greater effectiveness and safety when utilized in pregnant women with T1DM, patients with type 2 diabetes mellitus (T2DM), those undergoing hemodialysis, or individuals requiring surgery. Recent studies have also explored the impact of CLS therapy on quality of life, neurological function, and C-peptide levels. Nevertheless, despite these promising results, CLS still encounters challenges in clinical practice, such as technological maturity, cost-effectiveness, and personalized treatment approaches. Therefore, further research and development of CLS technology are imperative to facilitate its broader adoption among diverse populations and address the current obstacles to its implementation.","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46177447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats. 阿片生长因子升高改变1型糖尿病大鼠的边缘。
Pub Date : 2023-01-01 DOI: 10.33696/diabetes.4.054
Patricia J McLaughlin, Joseph W Sassani, David Diaz, Ian S Zagon

Ocular surface complications occur in more than 50% of individuals diagnosed with diabetes. The financial and health-related burden of diabetes is increasing annually. Several major ocular complications associated with diabetes involve the limbus. The vascular limbus, adjacent to the avascular cornea, is the source of circulating growth factors, elevated glucose, and cytokines for the cornea. The Opioid Growth Factor (OGF) - Opioid OGF Receptor (OGFr) axis is comprised of its effector peptide, OGF, [Met5]-enkephalin and the nuclear-associated receptor, OGFr, and has been demonstrated to be dysfunctional in diabetes with elevated serum and tissue levels of the inhibitory growth factor OGF recorded in corneal tissue. Little is known regarding the impact of OGF-OGFr axis dysregulation in diabetes on the functioning of the limbus constituents in support of corneal homeostasis. Adult male and female Sprague-Dawley rats were rendered hyperglycemic through intraperitoneal injections of streptozotocin (T1D); a subset of T1D rats received topical naltrexone (NTX) applied to the cornea and limbus daily for 8 weeks. At 4 and/or 8 weeks of hyperglycemia, different cohorts of animals were euthanized, eyes removed and processed for assessment of limbal morphology, expression of OGF, OGFr, cytokeratin 15, a marker for limbal cells, and Ki-67, a marker of proliferation. Limbal epithelial morphology (cell diameter, packing density) was altered in T1D male and female rats. OGF and OGFr were overexpressed in the limbus and CK15 expression was decreased, relative to normal control rats of the same sex. Blockade of the OGF- OGFr axis with NTX reversed limbal epithelial cell defects, and reduced OGF limbal tissue levels to those recorded in non-diabetic rats. In summary, OGF-OGFr axis dysregulation was observed in the limbus of T1D rats, contributing to the altered limbal morphology and delayed corneal surface healing observed in diabetic animals.

超过50%的糖尿病患者会出现眼表并发症。糖尿病的经济和健康负担每年都在增加。几种与糖尿病相关的主要眼部并发症涉及角膜缘。血管边缘邻近无血管角膜,是角膜循环生长因子、高血糖和细胞因子的来源。阿片生长因子(OGF) -阿片生长因子受体(OGFr)轴由其效应肽OGF, [Met5]-脑啡肽和核相关受体OGFr组成,已被证明在糖尿病中功能失调,角膜组织中记录的血清和组织中抑制生长因子OGF水平升高。关于糖尿病中OGF-OGFr轴失调对支持角膜内稳态的边缘成分功能的影响,我们知之甚少。通过腹腔注射链脲佐菌素使成年雄性和雌性Sprague-Dawley大鼠出现高血糖(T1D);T1D大鼠的一个亚组每天局部应用纳曲酮(NTX)于角膜和角膜缘,持续8周。在高血糖4周和/或8周时,对不同队列的动物实施安乐死,摘除眼睛,并进行评估角膜缘形态、OGF、OGFr、细胞角蛋白15(角膜缘细胞标志物)和Ki-67(增殖标志物)的表达。T1D雄性和雌性大鼠角膜缘上皮形态(细胞直径、堆积密度)发生改变。与同性别正常对照大鼠相比,边缘区OGF和OGFr过表达,CK15表达降低。用NTX阻断OGF- OGFr轴逆转了角膜缘上皮细胞缺陷,并将OGF角膜缘组织水平降低到非糖尿病大鼠的水平。综上所述,在T1D大鼠角膜边缘观察到OGF-OGFr轴失调,导致糖尿病动物角膜边缘形态改变和角膜表面愈合延迟。
{"title":"Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.","authors":"Patricia J McLaughlin,&nbsp;Joseph W Sassani,&nbsp;David Diaz,&nbsp;Ian S Zagon","doi":"10.33696/diabetes.4.054","DOIUrl":"https://doi.org/10.33696/diabetes.4.054","url":null,"abstract":"<p><p>Ocular surface complications occur in more than 50% of individuals diagnosed with diabetes. The financial and health-related burden of diabetes is increasing annually. Several major ocular complications associated with diabetes involve the limbus. The vascular limbus, adjacent to the avascular cornea, is the source of circulating growth factors, elevated glucose, and cytokines for the cornea. The Opioid Growth Factor (OGF) - Opioid OGF Receptor (OGFr) axis is comprised of its effector peptide, OGF, [Met<sup>5</sup>]-enkephalin and the nuclear-associated receptor, OGFr, and has been demonstrated to be dysfunctional in diabetes with elevated serum and tissue levels of the inhibitory growth factor OGF recorded in corneal tissue. Little is known regarding the impact of OGF-OGFr axis dysregulation in diabetes on the functioning of the limbus constituents in support of corneal homeostasis. Adult male and female Sprague-Dawley rats were rendered hyperglycemic through intraperitoneal injections of streptozotocin (T1D); a subset of T1D rats received topical naltrexone (NTX) applied to the cornea and limbus daily for 8 weeks. At 4 and/or 8 weeks of hyperglycemia, different cohorts of animals were euthanized, eyes removed and processed for assessment of limbal morphology, expression of OGF, OGFr, cytokeratin 15, a marker for limbal cells, and Ki-67, a marker of proliferation. Limbal epithelial morphology (cell diameter, packing density) was altered in T1D male and female rats. OGF and OGFr were overexpressed in the limbus and CK15 expression was decreased, relative to normal control rats of the same sex. Blockade of the OGF- OGFr axis with NTX reversed limbal epithelial cell defects, and reduced OGF limbal tissue levels to those recorded in non-diabetic rats. In summary, OGF-OGFr axis dysregulation was observed in the limbus of T1D rats, contributing to the altered limbal morphology and delayed corneal surface healing observed in diabetic animals.</p>","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Introducing m-Health and Digital Diabetes Apps in Clinical Pharmacy Education in Germany 在德国临床药学教育中引入移动健康和数字糖尿病应用程序
Pub Date : 2022-09-16 DOI: 10.33696/diabetes.4.051
{"title":"Introducing m-Health and Digital Diabetes Apps in Clinical Pharmacy Education in Germany","authors":"","doi":"10.33696/diabetes.4.051","DOIUrl":"https://doi.org/10.33696/diabetes.4.051","url":null,"abstract":"","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48100082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Customized Artificial Pancreas System with Neural Network based Model Predictive Control for Type 1 Diabetic Rats 基于神经网络的1型糖尿病大鼠模型预测控制定制人工胰腺系统
Pub Date : 2022-09-16 DOI: 10.33696/diabetes.4.049
Omer Batuhan Kirilmaz, M. Mahdavi, H. Ko, H. F. Lee, Sarah Park, G. Kwon
Omer Batuhan Kirilmaz1, Masoud Mahdavi1, Hoo Sang Ko1*, H. Felix Lee1, Sarah Park2, Guim Kwon3 1Department of Industrial Engineering, Southern Illinois University Edwardsville, Edwardsville, IL 62026, USA 2Research and Instructional Services, Duke University, Durham, NC 27708, USA 3Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, USA *Correspondence should be addressed to Hoo Sang Ko; hko@siue.edu
Omer Batuhan Kirilmaz1、Masoud Mahdavi1、Hoo Sang Ko1*、H.Felix Lee1、Sarah Park2、Guim Kwon3美国伊利诺伊州爱德华维尔市南伊利诺伊大学工业工程系2杜克大学研究与教学服务部,北卡罗来纳州达勒姆市27708,美国伊利诺伊州爱德华·维尔市,美国*通讯地址应为Hoo Sang Ko;hko@siue.edu
{"title":"A Customized Artificial Pancreas System with Neural Network based Model Predictive Control for Type 1 Diabetic Rats","authors":"Omer Batuhan Kirilmaz, M. Mahdavi, H. Ko, H. F. Lee, Sarah Park, G. Kwon","doi":"10.33696/diabetes.4.049","DOIUrl":"https://doi.org/10.33696/diabetes.4.049","url":null,"abstract":"Omer Batuhan Kirilmaz1, Masoud Mahdavi1, Hoo Sang Ko1*, H. Felix Lee1, Sarah Park2, Guim Kwon3 1Department of Industrial Engineering, Southern Illinois University Edwardsville, Edwardsville, IL 62026, USA 2Research and Instructional Services, Duke University, Durham, NC 27708, USA 3Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, USA *Correspondence should be addressed to Hoo Sang Ko; hko@siue.edu","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42082786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Emerging Target Protein Tyrosine Phosphatase 1B (PTP1B) for Type 2 Diabetes Mellitus Management 新出现的2型糖尿病治疗靶蛋白酪氨酸磷酸酶1B(PTP1B)
Pub Date : 2022-06-09 DOI: 10.33696/diabetes.3.048
Sónia Rocha, M. L. Corvo, E. Fernandes, M. Freitas
Sónia Rocha1, M. Luísa Corvo2, Eduarda Fernandes1*, Marisa Freitas1* 1LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 2Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal *Correspondence should be addressed to Marisa Freitas; marisafreitas@ff.up.pt, Eduarda Fernandes; egracas@ff.up.pt
Sónia Rocha1,M.Luísa Corvo2,Eduarda Fernandes 1*,Marisa Freitas1*1LAGV,REQUIMETE,波尔图大学药学院化学科学系应用化学实验室,4050-313葡萄牙波尔图2里斯本大学Farmácia Faculdade医学研究所,1649-003葡萄牙里斯本*通讯地址:Marisa Freidas;marisafreitas@ff.up.pt,爱德华·费尔南德斯;egracas@ff.up.pt
{"title":"The Emerging Target Protein Tyrosine Phosphatase 1B (PTP1B) for Type 2 Diabetes Mellitus Management","authors":"Sónia Rocha, M. L. Corvo, E. Fernandes, M. Freitas","doi":"10.33696/diabetes.3.048","DOIUrl":"https://doi.org/10.33696/diabetes.3.048","url":null,"abstract":"Sónia Rocha1, M. Luísa Corvo2, Eduarda Fernandes1*, Marisa Freitas1* 1LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 2Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal *Correspondence should be addressed to Marisa Freitas; marisafreitas@ff.up.pt, Eduarda Fernandes; egracas@ff.up.pt","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42196718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway. 糖尿病眼表并发症和OGF-OGFr通路失调的性别差异。
Pub Date : 2022-01-01 DOI: 10.33696/diabetes.4.052
Ian S Zagon, Joseph W Sassani, Patricia J McLaughlin

Background: Diabetes is a chronic disorder that affects more than 500 million individuals worldwide. It is a life-long disease with complications that attack nearly all other systems within the body. Although there is a slight increase in the prevalence of diabetes in males, ocular surface complications are equally present in males and females.

Aim: This review provides a discussion on preclinical studies related to the dysregulation of a biological pathway that appears to be causally related to diabetic ocular surface complications including dry eye, delayed corneal epithelial healing, and decreased corneal sensitivity. Most basic science and clinical studies focus on male sex in animal models in order to avoid confounders related to hormonal cycling. However, with approximately 10.2% of all women in the US aged 18-44 being diagnosed with diabetes and nearly 4% additional women having undiagnosed disease, it is prudent to examine the onset of these dysregulations also in females and to note any sex-related differences in the timing of onset or severity of ocular surface complications.

Summary: Data from several well-controlled investigations have documented that female rats with type 1 diabetes develop ocular surface complications before male rats. In part, this finding may be due to the increase in the inhibitory peptide Opioid Growth Factor (OGF) that occurs within 2 weeks of the induction of hyperglycemia in female animals in comparison to the changes in OGF levels in male rats which occur at 4 weeks. It was noted that estrogen levels drop within weeks of induction of hyperglycemia and could serve as another marker for the onset of disease activity and/or its complications. Finally, insulin does not appear to protect against early changes in OGF levels or estrogen secretion in diabetic female rats, setting the stage for a distinction in the disease profile of diabetes between males and females. These data encourage further studies on both sexes in order to establish a complete understanding of the underlying pathologies associated with complications associated with diabetes.

背景:糖尿病是一种慢性疾病,影响着全世界超过5亿人。这是一种伴随并发症的终身疾病,几乎会攻击身体的所有其他系统。虽然男性糖尿病患病率略有增加,但男性和女性的眼表并发症发生率相同。目的:本文综述了与糖尿病眼表并发症(包括干眼、角膜上皮愈合延迟和角膜敏感性降低)相关的生物通路失调的临床前研究。大多数基础科学和临床研究集中在雄性动物模型上,以避免与激素周期相关的混淆。然而,在美国18-44岁的女性中,约有10.2%被诊断为糖尿病,另有近4%的女性患有未确诊的疾病,因此检查女性中这些调节失调的发病情况,并注意在发病时间或眼表并发症严重程度上的性别差异是谨慎的。摘要:几项控制良好的研究数据表明,患有1型糖尿病的雌性大鼠比雄性大鼠更早出现眼表并发症。在某种程度上,这一发现可能是由于雌性动物诱导高血糖后2周内抑制肽阿片生长因子(OGF)的增加,而雄性大鼠的OGF水平变化发生在4周。有人指出,雌激素水平在诱导高血糖的几周内下降,可以作为疾病活动和/或其并发症发生的另一个标志。最后,在患有糖尿病的雌性大鼠中,胰岛素似乎并不能防止OGF水平或雌激素分泌的早期变化,这为雄性和雌性糖尿病疾病特征的区别奠定了基础。这些数据鼓励进一步对两性进行研究,以建立对糖尿病并发症相关的潜在病理的全面了解。
{"title":"Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway.","authors":"Ian S Zagon,&nbsp;Joseph W Sassani,&nbsp;Patricia J McLaughlin","doi":"10.33696/diabetes.4.052","DOIUrl":"https://doi.org/10.33696/diabetes.4.052","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is a chronic disorder that affects more than 500 million individuals worldwide. It is a life-long disease with complications that attack nearly all other systems within the body. Although there is a slight increase in the prevalence of diabetes in males, ocular surface complications are equally present in males and females.</p><p><strong>Aim: </strong>This review provides a discussion on preclinical studies related to the dysregulation of a biological pathway that appears to be causally related to diabetic ocular surface complications including dry eye, delayed corneal epithelial healing, and decreased corneal sensitivity. Most basic science and clinical studies focus on male sex in animal models in order to avoid confounders related to hormonal cycling. However, with approximately 10.2% of all women in the US aged 18-44 being diagnosed with diabetes and nearly 4% additional women having undiagnosed disease, it is prudent to examine the onset of these dysregulations also in females and to note any sex-related differences in the timing of onset or severity of ocular surface complications.</p><p><strong>Summary: </strong>Data from several well-controlled investigations have documented that female rats with type 1 diabetes develop ocular surface complications before male rats. In part, this finding may be due to the increase in the inhibitory peptide Opioid Growth Factor (OGF) that occurs within 2 weeks of the induction of hyperglycemia in female animals in comparison to the changes in OGF levels in male rats which occur at 4 weeks. It was noted that estrogen levels drop within weeks of induction of hyperglycemia and could serve as another marker for the onset of disease activity and/or its complications. Finally, insulin does not appear to protect against early changes in OGF levels or estrogen secretion in diabetic female rats, setting the stage for a distinction in the disease profile of diabetes between males and females. These data encourage further studies on both sexes in order to establish a complete understanding of the underlying pathologies associated with complications associated with diabetes.</p>","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Colchicine in COVID-19 —The Colcorona Trial 秋水仙碱治疗新冠肺炎-Colcorona试验
Pub Date : 2021-10-10 DOI: 10.33696/diabetes.3.046
P. L. D. Luz
Colcorona was a multicenter, international study promoted by the Montreal Heart Institute, Canada, whose main objective was to test the effects of colchicine in non-hospitalized patients with COVID-19 [1]. So far, the majority of studies addressed hospitalized patients which is understandable since mortality occurs mainly among those individuals. The Colcorona, however, focused specifically in non-hospitalized patients because preventing hospitalization and death are important therapeutic targets. Inclusion criteria were age ≥ 40 years, one or more risk factors, including arterial hypertension, heart failure, diabetes, coronary disease, fever, age ≥ 70 years or obesity. Diagnosis was based on positive PCR from nasal swab. Given restriction in PCR swab at beginning of the pandemic, a minority of patients were enrolled based on clinical criteria. The initial intention was to enroll 6,000 patients in a randomized, double-blind approach, comparing colchicine – 0.5 mg twice daily for the initial 3 days, followed by 0.5 mg daily for the following 27 days vs. a placebo. However, the study was terminated with 75% of enrollment for logistical reasons; thus 4,488 patients were included of whom 2,235 received colchicine and 2,253 the placebo [1].
Colcorona是一项由加拿大蒙特利尔心脏研究所推动的多中心国际研究,其主要目的是测试秋水仙碱对未住院的COVID-19[1]患者的影响。到目前为止,大多数研究都是针对住院病人的,这是可以理解的,因为死亡主要发生在这些人身上。然而,Colcorona专门针对非住院患者,因为预防住院和死亡是重要的治疗目标。纳入标准为年龄≥40岁、一个或多个危险因素,包括动脉高血压、心力衰竭、糖尿病、冠状动脉疾病、发热、年龄≥70岁或肥胖。诊断基于鼻拭子PCR阳性。鉴于在大流行开始时对PCR拭子的限制,根据临床标准纳入了少数患者。最初的目的是在随机双盲方法中招募6000名患者,比较秋水仙碱-最初3天每天0.5 mg两次,随后27天每天0.5 mg与安慰剂。然而,由于后勤原因,75%的入组者终止了研究;因此纳入了4488例患者,其中2235例接受秋水仙碱治疗,2253例接受安慰剂治疗。
{"title":"Colchicine in COVID-19 —The Colcorona Trial","authors":"P. L. D. Luz","doi":"10.33696/diabetes.3.046","DOIUrl":"https://doi.org/10.33696/diabetes.3.046","url":null,"abstract":"Colcorona was a multicenter, international study promoted by the Montreal Heart Institute, Canada, whose main objective was to test the effects of colchicine in non-hospitalized patients with COVID-19 [1]. So far, the majority of studies addressed hospitalized patients which is understandable since mortality occurs mainly among those individuals. The Colcorona, however, focused specifically in non-hospitalized patients because preventing hospitalization and death are important therapeutic targets. Inclusion criteria were age ≥ 40 years, one or more risk factors, including arterial hypertension, heart failure, diabetes, coronary disease, fever, age ≥ 70 years or obesity. Diagnosis was based on positive PCR from nasal swab. Given restriction in PCR swab at beginning of the pandemic, a minority of patients were enrolled based on clinical criteria. The initial intention was to enroll 6,000 patients in a randomized, double-blind approach, comparing colchicine – 0.5 mg twice daily for the initial 3 days, followed by 0.5 mg daily for the following 27 days vs. a placebo. However, the study was terminated with 75% of enrollment for logistical reasons; thus 4,488 patients were included of whom 2,235 received colchicine and 2,253 the placebo [1].","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47592373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Recommendations for T2D Management: Beneficial Impact of Exerkines on Pancreatic ?-Cells Function and Glucose Homeostasis in Skeletal Muscle T2D治疗的新建议:运动素对胰腺细胞功能和骨骼肌葡萄糖稳态的有益影响
Pub Date : 2021-10-10 DOI: 10.33696/diabetes.3.045
A. Langlois, Julie Vion, A. Dumond, M. Pinget, K. Bouzakri
Nowadays, physical activity is strongly considered as an effective strategy in both preventing and treating type 2 diabetes (T2D) [1,2]. Indeed, it is well established that exercises improve β-cell insulin signaling, insulin secretion, prevent pancreatic β-cell failure and impacts glucose homeostasis regulation in T2D patients [3-8]. Moreover, exercise has clearly shown to improve the peripheral insulin sensitivity in T2D patients and to have a beneficial effect on insulin resistance [9-12]. The improvement of peripheral insulin sensitivity in T2D patients and the beneficial effect on insulin resistance by the exercise have been widely documented. For these Abstract
目前,体育活动被认为是预防和治疗2型糖尿病(T2D)的有效策略[1,2]。事实上,运动可以改善β细胞胰岛素信号传导、胰岛素分泌,防止胰腺β细胞衰竭,影响t2dm患者的葡萄糖稳态调节[3-8]。此外,运动已明确显示可以改善T2D患者的外周胰岛素敏感性,并对胰岛素抵抗有有益作用[9-12]。运动对t2dm患者外周胰岛素敏感性的改善和对胰岛素抵抗的有益作用已被广泛报道。对于这些摘要
{"title":"New Recommendations for T2D Management: Beneficial Impact of Exerkines on Pancreatic ?-Cells Function and Glucose Homeostasis in Skeletal Muscle","authors":"A. Langlois, Julie Vion, A. Dumond, M. Pinget, K. Bouzakri","doi":"10.33696/diabetes.3.045","DOIUrl":"https://doi.org/10.33696/diabetes.3.045","url":null,"abstract":"Nowadays, physical activity is strongly considered as an effective strategy in both preventing and treating type 2 diabetes (T2D) [1,2]. Indeed, it is well established that exercises improve β-cell insulin signaling, insulin secretion, prevent pancreatic β-cell failure and impacts glucose homeostasis regulation in T2D patients [3-8]. Moreover, exercise has clearly shown to improve the peripheral insulin sensitivity in T2D patients and to have a beneficial effect on insulin resistance [9-12]. The improvement of peripheral insulin sensitivity in T2D patients and the beneficial effect on insulin resistance by the exercise have been widely documented. For these Abstract","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46677164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysregulation of the OGF-OGFr pathway and associated diabetic complications. OGF-OGFr通路失调及相关的糖尿病并发症。
Pub Date : 2021-09-27 DOI: 10.33696/diabetes.3.041
P. McLaughlin, J. Sassani, I. Zagon
BackgroundDiabetes is a worldwide epidemic with more than 550 million individuals expected to be diagnosed with the disease by 2030. Complications associated with diabetes affect nearly all systems, but more than 54% of diabetic individuals have ocular surface disorders including keratopathy, dry eye or altered corneal surface sensitivity, and nearly 70% experience slow healing foot ulcers which if left untreated, can lead to amputation. There is new information regarding the underlying pathophysiology associated with these complications, as well as potential treatment.AimThis commentary assembles data on preclinical studies showing that corneal surface complications such as dry eye and sensitivity, as well as delayed epithelial wound healing in the cornea and skin in diabetic rats and mice, correlate with a dysregulation of the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) regulatory axis. The peptide in this pathway, OGF, chemically termed [Met5]-enkephalin, is elevated in the serum of humans and animals with either type 1 or type 2 diabetes. The cause for this finding is unknown. However, there are studies that demonstrate that blockade of the interactions between OGF (or elevated levels of OGF) and its receptor can reverse and, in some cases, prevent the onset of diabetic corneal complications. Clinicians and healthcare workers need to recognize this fundamental pathophysiology leading to diabetic complications.SummaryDysfunction of the OGF-OGFr growth regulatory system plays a role in the development of ocular surface complications and delayed cutaneous wound healing complications in multiple animal models of both Type 1 and Type 2 diabetes. Modulation of this system may hold promise for reversing or even preventing these diabetic complications in humans. Moreover, monitoring serum levels of OGF should be investigated as an indicator of the development of these and other diabetic complications.
糖尿病是一种全球性流行病,预计到2030年将有超过5.5亿人被诊断患有这种疾病。糖尿病相关并发症几乎影响所有系统,但超过54%的糖尿病患者患有眼表疾病,包括角膜病变、干眼或角膜表面敏感性改变,近70%的糖尿病患者患有愈合缓慢的足部溃疡,如果不及时治疗,可能导致截肢。关于这些并发症的潜在病理生理学以及潜在的治疗方法,有了新的信息。目的:本评论收集了临床前研究数据,表明糖尿病大鼠和小鼠角膜表面并发症,如干眼和敏感性,以及角膜和皮肤上皮伤口愈合延迟,与阿片生长因子(OGF)-阿片生长因子受体(OGFr)调节轴的失调相关。该途径中的肽OGF,化学名称为[Met5]-脑啡肽,在患有1型或2型糖尿病的人和动物血清中升高。这一发现的原因尚不清楚。然而,有研究表明,阻断OGF(或OGF水平升高)与其受体之间的相互作用可以逆转,并在某些情况下预防糖尿病角膜并发症的发生。临床医生和卫生保健工作者需要认识到导致糖尿病并发症的基本病理生理学。在多种1型和2型糖尿病动物模型中,OGF-OGFr生长调节系统的功能障碍在眼表并发症和延迟皮肤伤口愈合并发症的发生中起作用。调节这一系统有望逆转甚至预防人类的糖尿病并发症。此外,监测血清OGF水平应作为这些和其他糖尿病并发症发展的指标进行研究。
{"title":"Dysregulation of the OGF-OGFr pathway and associated diabetic complications.","authors":"P. McLaughlin, J. Sassani, I. Zagon","doi":"10.33696/diabetes.3.041","DOIUrl":"https://doi.org/10.33696/diabetes.3.041","url":null,"abstract":"Background\u0000Diabetes is a worldwide epidemic with more than 550 million individuals expected to be diagnosed with the disease by 2030. Complications associated with diabetes affect nearly all systems, but more than 54% of diabetic individuals have ocular surface disorders including keratopathy, dry eye or altered corneal surface sensitivity, and nearly 70% experience slow healing foot ulcers which if left untreated, can lead to amputation. There is new information regarding the underlying pathophysiology associated with these complications, as well as potential treatment.\u0000\u0000\u0000Aim\u0000This commentary assembles data on preclinical studies showing that corneal surface complications such as dry eye and sensitivity, as well as delayed epithelial wound healing in the cornea and skin in diabetic rats and mice, correlate with a dysregulation of the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) regulatory axis. The peptide in this pathway, OGF, chemically termed [Met5]-enkephalin, is elevated in the serum of humans and animals with either type 1 or type 2 diabetes. The cause for this finding is unknown. However, there are studies that demonstrate that blockade of the interactions between OGF (or elevated levels of OGF) and its receptor can reverse and, in some cases, prevent the onset of diabetic corneal complications. Clinicians and healthcare workers need to recognize this fundamental pathophysiology leading to diabetic complications.\u0000\u0000\u0000Summary\u0000Dysfunction of the OGF-OGFr growth regulatory system plays a role in the development of ocular surface complications and delayed cutaneous wound healing complications in multiple animal models of both Type 1 and Type 2 diabetes. Modulation of this system may hold promise for reversing or even preventing these diabetic complications in humans. Moreover, monitoring serum levels of OGF should be investigated as an indicator of the development of these and other diabetic complications.","PeriodicalId":73706,"journal":{"name":"Journal of diabetes and clinical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47792246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Journal of diabetes and clinical research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1